|Dr. Pavan Cheruvu M.D.||CEO & Director||N/A||N/A||1982|
|Dr. Gregory M. Weinhoff||Principal Financial & Accounting Officer||561.03k||N/A||1971|
|Mr. Mark Altmeyer||Pres & Chief Commercial Officer of Axovant Sciences GmbH||N/A||N/A||1961|
|Dr. David T. Hung||Scientific Advisor of Group||N/A||N/A||1958|
|Dr. Fraser Wright||Chief Technology Officer||N/A||N/A||N/A|
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Axovant Sciences Ltd.’s ISS Governance QualityScore as of October 1, 2018 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 2; Compensation: 10.